title: When Can a Salvage Therapy (T-DM1) Take the Lead?
authors.affiliation: Sylvester Comprehensive Cancer Center, Deerfield Beach, FL.
authors.forename: Reshma L
authors.initials: RL
authors.lastname: Mahtani
authors.affiliation: Sylvester Comprehensive Cancer Center, Deerfield Beach, FL.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Vogel
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001943:Breast Neoplasms; D006801:Humans; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D016879:Salvage Therapy; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab